PFM Health Sciences’s Axsome Therapeutics AXSM Stock Holding History

PFM Health Sciences’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$44.7M	Buy	264,304 +12,742	+5%	+$2.2M	4.07%	5
2025 Q4	$45.9M	Sell	251,562 -278,770	-53%	-$38.9M	4.58%	3
2025 Q3	$64.4M	Buy	530,332 +47,227	+10%	+$5.32M	4.95%	4
2025 Q2	$50.4M	Sell	483,105 -73,440	-13%	-$7.78M	4.29%	4
2025 Q1	$64.9M	Buy	556,545 +89,118	+19%	+$10.2M	4.71%	5
2024 Q4	$39.5M	Hold	467,427	–	–	2.45%	10
2024 Q3	$42M	Hold	467,427	–	–	2.38%	14
2024 Q2	$37.6M	Hold	467,427	–	–	1.86%	17
2024 Q1	$37.3M	Hold	467,427	–	–	1.75%	19
2023 Q4	$37.2M	Sell	467,427 -55,783	-11%	-$3.73M	2.23%	15
2023 Q3	$36.6M	Buy	523,210 +27,628	+6%	+$2.07M	1.72%	27
2023 Q2	$35.6M	Sell	495,582 -110,499	-18%	-$8.15M	1.38%	33
2023 Q1	$37.4M	Sell	606,081 -486,750	-45%	-$32M	1.65%	27
2022 Q4	$84.3M	Sell	1,092,831 -566,902	-34%	-$33.9M	3.02%	7
2022 Q3	$74.1M	Buy	1,659,733 +299,137	+22%	+$14.9M	2.68%	8
2022 Q2	$52.1M	Buy	+1,360,596	New	+$43M	1.99%	15

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PFM Health Sciences's AXSM Position: Q1 2026 in Review

PFM Health Sciences increased its Axsome Therapeutics (AXSM) stake by 5.1% in Q1 2026, buying an estimated $2.2M and bringing the position to 264,304 shares worth $44.7M. The position accounts for 4.07% of the portfolio, ranked #5.

PFM Health Sciences first reported a position in AXSM in Q2 2022 and has held it in 16 quarters since. The position peaked at $84.3M in Q4 2022. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

PFM Health Sciences held 264,304 shares of Axsome Therapeutics worth $44.7M as of Q1 2026.
PFM Health Sciences bought 12,742 Axsome Therapeutics shares in Q1 2026, an estimated $2.2M.
Axsome Therapeutics made up 4.07% of PFM Health Sciences's portfolio in Q1 2026, its #5 holding.
PFM Health Sciences first reported a position in Axsome Therapeutics in Q2 2022 and has held it in 16 quarters since.
PFM Health Sciences's Axsome Therapeutics position peaked at $84.3M in Q4 2022.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on PFM Health Sciences's 13F filing for Q1 2026, filed 15 May 2026.